Jump to content
World's Largest Herpes Support Group
Sign in to follow this  
Eosino

Diagnosed at 19

Recommended Posts

Eosino

Hi there,

I just got my diagnosis today. I have been with my current boyfriend for 7 months. He has never had a herpes outbreak before in his life and neither have i. We both got our first outbreak at the same time. I went to the doctor and got it swabbed and it turned out to be genital herpes. :(

The doctor told me next to nothing about caring for myself with this virus. I have been doing a lot of research and it has helped me understand it a lot better.

My question is: what hygiene measures should i follow?

Thanks.

Share this post


Link to post
Share on other sites
how

I'm also 19 and know exactly what your going through...My boyfriend and I have been together for over three years and we have neither even slept with anyone but each other, turns out, he used to get cold sores and he had been sick and ended up accidently giving it to me genitally...You really need to get a blood test too because the culture isn't always 100%. As for how to take care of it, just keep it dry, and wear loose underwear or just a loose pair of sweat pants or something like that. Did the doctor give you anything to numb the pain or are you even hurting? Either way the best thing to do is just keep it dry, hope this helped you atleast a little.

Share this post


Link to post
Share on other sites
boopboop

Hey,

Hygiene wise just do same as you did before....best to clean with water or ph balenced stuff....cleaning too much will give you thrush. And always wash your hands after going near that area....but u would have done that pre-H.. so nothing changes really.

Just look after yourself...is pics of some vitamins and bath stuff that can help with outbreaks in my album. You'll be fine, herpes is just a nuisance that stops you having a sex once in a while...don't make it any bigger in your head!!!

x

Share this post


Link to post
Share on other sites
Eosino

The doctor didn't give me anything and he really didn't say much. He didn't even sit down to tell me the news. He stood by the door hovering over me. :( He just said that the next time i feel an outbreak happening i should go to the clinic to get a prescription for Valtrex. Which i don't think helps me because it seems to be a very expensive drug that i can't afford right now.

I had an argument with my boyfriend this morning. He said that reading up about herpes and educating myself is making myself a slave to the virus and letting it rule my life. All i want to do is know the facts so that i know how to take care of myself. He apparently thinks that i shouldn't even be learning about what foods to eat and what foods to avoid. Please tell me he is just being negative. :( Even though he has Herpes too, he is being very insensitive and unsupportive about the whole thing.

I know he is wrong, but i just need to hear someone else tell me so.

Share this post


Link to post
Share on other sites
Lost321

Claudia91,

It is important to be correctly informed. I was diagnosed a week ago, and I have been trying to become knowledgeable about it as much as I can. I have also been trying to figure out what I can do to prevent outbreaks like what to eat and what not to eat. However, I also realize as important as it is to get as much information on it as possible that I also have to eventually try to live as much a life like I used to as possible because I can't stay in my room crying or reading webpages all the time. If I do that then I've allowed "H" to control my life when I should be the one taking control... My thinking is still new with regard to "H;" I still have trouble saying the word... For yourself (as I believe for myself) it is important to get to know your body and become informed about what can help you. I've found out just from becoming a member yesterday of how supportive people on here can be. I'm thankful to know that I can come on here and just really talk about it without being judged. It's important to have support too. Know that you aren't alone, and it is a GOOD thing to become informed just don't let it prevent you from living a little. All the best :)

Share this post


Link to post
Share on other sites
Eosino

My outlook is positive. I only cried about it for about 2 minutes and then i decided that there is no use being sad about it because it's going to be with me for the rest of my life. My boyfriend's strategy is to ignore it and not do much, the flaw in that is that he's not very healthy to begin with. :( I'm going to take care of myself and educate myself as much as i can and if he can't handle that, then it's his loss. Also, i just got diagnosed yesterday. It's very ignorant of him to tell me that i shouldn't think about it. It's going to be on my brain for a little while and then i will put it at the back of my mind.

Thanks for all the help. :)

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Sign in to follow this  

  • The Hive is Thriving!

    • Total Topics
      70,110
    • Total Posts
      473,852
  • Posts

    • RNY18
      https://markets.businessinsider.com/news/stocks/x-vax-technology-raises-56-million-in-upsized-series-a-financing-to-advance-lead-herpes-vaccine-program-1028376554 Add ∆gD-2 (delta gD-2) to the list ! "We believe that ∆gD-2 may be more promising than other previous vaccine candidates because it elicits a different type of immune response against HSV-1 and HSV-2 that is more effective in preclinical models at clearing virus and preventing the establishment of latency. In nonclinical models, immunization with ∆gD-2 elicits antibodies that facilitate the killing of infected cells, rapidly clearing the virus and thereby inducing sterilizing immunity," added William Jacobs, PhD, co-Inventor and Professor of Microbiology & Immunology at Albert Einstein College of Medicine."...
    • RNY18
      More X-Vax Info : https://markets.businessinsider.com/news/stocks/x-vax-technology-raises-56-million-in-upsized-series-a-financing-to-advance-lead-herpes-vaccine-program-1028376554 "We believe that ∆gD-2 may be more promising than other previous vaccine candidates because it elicits a different type of immune response against HSV-1 and HSV-2 that is more effective in preclinical models at clearing virus and preventing the establishment of latency. In nonclinical models, immunization with ∆gD-2 elicits antibodies that facilitate the killing of infected cells, rapidly clearing the virus and thereby inducing sterilizing immunity," added William Jacobs, PhD, co-Inventor and Professor of Microbiology & Immunology at Albert Einstein College of Medicine..."
    • RNY18
      They may not cure HSV but it looks like they are taking positive steps against HIV : https://timesofindia.indiatimes.com/life-style/health-fitness/he alth-news/hiv-cure-soon-human-trials-underway-in-china/articleshow/70316379.cms   "Hopefully, the second-phase trial will be completed in the latter half of 2021, and the third-phase clinical trial may start at the end of that year, which will involve thousands of volunteers in a trial to test the effectiveness of the vaccine to protect people against HIV," the researcher added."...  
    • RNY18
      Got this this morning, definitely positive news. Still seems so far off....
    • RNY18
      X-Vax Technology Raises $56 Million in Upsized Series A Financing to Advance Lead Herpes Vaccine Program A new approach to beating herpes by inducing antibodies that mediate the killing of infected cells Participants include Johnson & Johnson Innovation – JJDC, Inc. (JJDC); Adjuvant Capital, an impact investment fund supported by the Bill & Melinda Gates Foundation as an anchor investor; Serum Institute of India; Alexandria Venture Investments; Founders Fund.  JUPITER, FL, July 23, 2019. X-Vax Technology, Inc. (X-VAX), a biotechnology company developing vaccines based on a new approach that mediates the killing of infected cells, today announced that it has raised $56 million in an upsized Series A financing with participation from strategic and institutional investors, including Johnson & Johnson Innovation – JJDC, Inc. (JJDC); Adjuvant Capital, an impact investment fund supported by the Bill & Melinda Gates Foundation as an anchor investor; Serum Institute of India; Alexandria Venture Investments; and FF DSF VI, a scout investment vehicle out of Founders Fund. Proceeds from the financing will be used to advance X-VAX’s lead program, a vaccine candidate against herpes, called ∆gD-2 (delta gD-2) for further development and production, including a Phase 1 clinical study.   “We are pleased to have the support of our new and existing investors as we continue to build our leadership position in the development of a herpes vaccine,” said Ulf Wiinberg, President and Chief Executive Officer of X-VAX. “We are encouraged by the preclinical data for our new approach to beating herpes and creating a potentially world-changing vaccine.”    “Herpes infections are a significant global health problem that affect all age groups from infants to the elderly. Infection is associated with a wide range of disease,” said Betsy Herold, MD, co-Inventor and Professor of Pediatrics, Microbiology & Immunology at Albert Einstein College of Medicine in New York. “The ability of the virus to successfully escape clearance by the immune system and to establish a non-replicating state known as latency with periodic reactivation results in lifelong infection and ongoing risk of transmission.”    “We believe that ∆gD-2 may be more promising than other previous vaccine candidates because it elicits a different type of immune response against HSV-1 and HSV-2 that is more effective in preclinical models at clearing virus and preventing the establishment of latency. In nonclinical models, immunization with ∆gD-2 elicits antibodies that facilitate the killing of infected cells, rapidly clearing the virus and thereby inducing sterilizing immunity,” added William Jacobs, PhD, co-Inventor and Professor of Microbiology & Immunology at Albert Einstein College of Medicine.   Maxim Merchant Capital, a division of Maxim Group LLC, acted as sole placement agent for the financing.   About herpes, a global epidemic There is no approved vaccine for herpes simplex. Herpes simplex virus is categorized into 2 types: herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2). More than 3.7 billion people under the age of 50 around the world are infected with HSV-1, while over 400 million have HSV-2. Neonatal infection can be devastating, at 60% fatality without treatment. Other complications include encephalitis or meningitis (inflammation of the brain or the tissue that covers the brain and spinal cord), and infectious blindness. HSV-2 is also known to contribute significantly to the spread of HIV. Antiviral drug therapy shows only moderate efficacy and comes with significant side effects. Attempts to develop an effective vaccine have repeatedly failed.   About X-Vax Technology, Inc. We are a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Our research leads us to believe that the new approach we are taking could succeed in defeating herpes. We have created a herpes vaccine candidate that we call ∆gD-2 (delta gD-2) because it is based on an HSV-2 virus genetically deleted for glycoprotein D (gD-2). With it, we have been able to prevent infections caused by herpes type 1 (HSV-1) and type 2 (HSV-2) in multiple preclinical models—with encouraging results. The vaccine induces Fc receptor activating antibodies that mediate antibody-dependent cell-mediated killing (ADCK) as the primary mechanism of protection. ADCK is induced to flag infected cells for destruction by natural immune cells.   Forward-looking statements This news release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, we are using forward-looking statements when we discuss the proposed use of proceeds from the Series A financing, when we describe our belief that our new approach to beating herpes could succeed in potentially creating a world-changing vaccine, when we discuss the belief that our vaccine candidate is more promising than other previous vaccine candidates and when we state our belief that our new approach could succeed in defeating herpes. These forward-looking statements and their implications are based on the current expectations of the management of X-VAX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation may adversely impact us inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of X-VAX to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.    Contact Andreas Eggert aeggert@x-vax.com +1-561-517-XVAX (+1-561-517-9829)   x-vax.com  
×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.